据悉，耐赋康作为全球首个获得美国食品药品监督管理局（FDA）和欧洲药品管理局（EMA）完全批准的IgA肾病治疗药物，于2023年11月通过优先审评程序正式获得中国国家药品监督管理局(NMPA)的批准，用于治疗原发性IgA肾病的成年患者，是中国唯一获得IgA肾病适应症的治疗药物。China Dingxin-B (01952) reached a high of 40.5 Hong Kong dollars in the morning session, hitting a new high since January 2022. It is worth noting that China Dingxin has continued to rise since the end of August, with the stock price doubling in the past three months.
According to the Wisdom Finance APP, China Dingxin-B (01952) reached a high of 40.5 Hong Kong dollars in the morning session, hitting a new high since January 2022. It is worth noting that China Dingxin has been continuously rising since the end of August, with the stock price doubling in the past three months.
On the news front, China Dingxin (01952) announced that Nephrocon (Budesonide Enteric Capsule, NEFECON) has been successfully included in the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2024)". The new version of the National Medical Insurance Drug List will officially take effect on January 1, 2025. Nephrocon was successfully included in the national medical insurance drug list in its first negotiation, proving once again that it is an innovative drug that fills clinical gaps, meets the urgent needs of patients, and has excellent efficacy and safety.
It is reported that as the world's first IgA nephropathy treatment drug to receive full approval from the Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA), Nephrocon officially obtained approval from the China National Medical Products Administration (NMPA) through priority review in November 2023, for the treatment of adult patients with primary IgA nephropathy. It is the only treatment drug in China approved for the indication of IgA nephropathy.
